hydroxylase-biology
(2)
Steven Everett
Steven Everett is a biotechnology executive and cancer scientist who founded MaveriX Oncology in Palo Alto, California, where he serves as President and CEO. With a background rooted in more than two decades of cancer research at the University of Oxford, University of Dundee and UCSF, he has built his career around a single idea: making cancer drugs that switch on only inside tumors. At MaveriX he is developing conditionally activated small-molecule therapeutics that exploit hydroxylase biology in the tumor immune microenvironment, aiming to hit cancer hard while sparing healthy tissue.
MaveriX Oncology, Inc.
MaveriX Oncology is a Palo Alto biotech developing conditionally activated small molecule drug conjugates (CA-SMDCs) that exploit tumor-associated hydroxylase biology to deliver cytotoxic and immunomodulatory payloads selectively to solid tumors. Its IMPACT-2X platform aims to widen the therapeutic window of chemotherapy and immunotherapy, killing cancer cells while turning 'cold' immunosuppressive tumors 'hot.' Founded by veteran oncology drug developers and backed by PPF Group and SOTIO, the company's lead program is MVX-5005.